Home Cart Sign in  
Chemical Structure| 1847461-43-1 Chemical Structure| 1847461-43-1

Structure of Mobocertinib
CAS No.: 1847461-43-1

Chemical Structure| 1847461-43-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TAK-788 is an investigational TKI with potent, selective preclinical activity against activating EGFR and HER2 mutations, including exon 20 insertions. It is in a phase 1/2 open-label, multicenter study.

Synonyms: TAK-788; AP32788

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mobocertinib

CAS No. :1847461-43-1
Formula : C32H39N7O4
M.W : 585.70
SMILES Code : O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C
Synonyms :
TAK-788; AP32788
MDL No. :MFCD32669806
InChI Key :AZSRSNUQCUDCGG-UHFFFAOYSA-N
Pubchem ID :118607832

Safety of Mobocertinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Mobocertinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03811834 Healthy Volunteers PHASE1 COMPLETED 2019-03-11 Celerion, Lincoln, Nebraska, 6... More >>8502, United States Less <<
NCT04056455 Renal Impairment|Healthy Volun... More >>teers Less << PHASE1 COMPLETED 2022-04-20 Clinical Pharmacology of Miami... More >>, Hialeah, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT04056468 Hepatic Impairment|Healthy Vol... More >>unteers Less << PHASE1 COMPLETED 2022-02-26 Clinical Pharmacology of Miami... More >>, Hialeah, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States Less <<
NCT02716116 Carcinoma, Non-Small-Cell Lung PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-03-28 Brookwood Medical Center, Birm... More >>ingham, Alabama, 35209, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, 85234, United States|The Oncology Institute of Hope and Innovation - West Tucson, Tucson, Arizona, 85745, United States|City of Hope Comprehensive Cancer Center - Duarte, Duarte, California, 91010, United States|Compassionate Cancer Care - Fountain Valley, Fountain Valley, California, 92708, United States|University of California San Diego Moores Cancer Center, La Jolla, California, 92093, United States|Pacific Shores Medical Group-Long Beach Elm, Long Beach, California, 90813, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, 90720, United States|University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange, California, 92868, United States|Stanford Cancer Center - Palo Alto, Palo Alto, California, 94305, United States|SLO Oncology and Hematology Health Center, San Luis Obispo, California, 93405, United States|The Oncology Institute of Hope and Innovation, Whittier, California, 90603, United States|University of Colorado Cancer Center, Aurora, Colorado, 80045, United States|AdventHealth Orlando, Orlando, Florida, 32804, United States|Winship Cancer Institute, Atlanta, Georgia, 30322, United States|The University of Chicago Medicine, Chicago, Illinois, 60637, United States|Investigative Clinical Research - Indiana, Indianapolis, Indiana, 46260, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Siteman Cancer Center - Washington University Medical Campus, Saint Louis, Missouri, 63110, United States|Atlantic Health - Morristown Medical Center, Morristown, New Jersey, 07960, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Levine Cancer Institute, Charlotte, North Carolina, 28203, United States|Carolinas Healthcare System, Charlotte, North Carolina, 28204, United States|Hightower Clinical, Oklahoma City, Oklahoma, 73102, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Thompson Oncology Group - Knoxville - Downtown, Knoxville, Tennessee, 37916, United States|SCRI - Tennessee Oncology - Nashville - Centennial, Nashville, Tennessee, 37203, United States|University of Virginia Cancer Center, Nashville, Tennessee, 37232, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States|Lumi Research, Houston, Texas, 77090, United States|University of Virginia Cancer Center, Charlottesville, Virginia, 22908, United States|Virginia Cancer Specialists - Fairfax Office, Fairfax, Virginia, 22031, United States|Swedish Cancer Institute, Seattle, Washington, 98104, United States|Peking University Cancer Hospital/Beijing Cancer Hospital, Beijing, Beijing, 100036, China|Beijing Chest Hospital, Beijing, Beijing, 101149, China|Hubei Cancer Hospital, Wuhan, Hubei, 430079, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, 200433, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310003, China|Thoraxklinik Heidelberg, Heidelberg, Baden-wuerttemberg, 69126, Germany|HELIOS Klinikum Emil von Behring, Berlin, 14165, Germany|Istituto Di Ricovero E Cura A Carattere Scientifico - Istituto Europeo Di Oncologia, Milano, 20141, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, 43126, Italy|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|Kurume University Hospital, Kurume-shi, Fukuoka, 830-0011, Japan|Sendai Kousei Hospital, Sendai, Miyagi, 980-0873, Japan|Kindai University Hospital, Osaka-sayama, Osaka, 589-8511, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Severance Hospital, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|In Situ Global Clinical Trials Network, Manati, 00674, Puerto Rico|Complejo Hospitalario Universitario A Coruna, A Coruna, LA Coruna, 15006, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clinic de Barcelona, Barcelona, 08036, Spain|National Cheng Kung University Hospital, Tainan, Tainan CITY, 70403, Taiwan|National Taiwan University Hospital - YunLin Branch, Douliu, Yunlin, 640, Taiwan|Taichung Veterans General Hospital, Taichung, 407, Taiwan|National Taiwan University Hospital, Taipei, 100, Taiwan|The Royal Marsden NHS Foundation Trust, London, England, SW3 6JJ, United Kingdom Less <<
NCT03807778 Non-Small Cell Lung Cancer PHASE1 ACTIVE_NOT_RECRUITING 2025-03-31 Aichi Cancer Center Hospital, ... More >>Nagoya, Aichi, Japan|Fujita Health University Hospital, Toyoake, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hyogo Cancer Cente, Akashi, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Okayama University Hospital, Kita-ku, Okayama, Japan|Kansai Medical University Hospital, Hirakata, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan|Saitama Cancer Center, Ina, Saitama, Japan|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Cancer Institute Hospital, Koto-ku, Tokyo, Japan|Yamaguchi Ube Medical Center, Ube, Yamaguchi, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kyoto University Hospital, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka International Cancer Institute, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Wakayama Medical University Hospital, Wakayama, Japan Less <<
NCT04441255 Healthy Volunteers PHASE1 COMPLETED 2020-08-10 Celerion, Lincoln, Nebraska, 6... More >>8502, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.71mL

0.34mL

0.17mL

8.54mL

1.71mL

0.85mL

17.07mL

3.41mL

1.71mL

References

 

Historical Records

Categories